AstraZeneca's Ultomiris scores its 3rd FDA approval, setting up market clash with argenx

Thursday, Ultomiris continued its rapid ascent with an FDA approval to treat generalized myasthenia gravis (gMG), an autoimmune neuromuscular disorder that causes severe weakness and loss of muscle function.